Prognostic Effect of Lymphocyte Subgroup CD4+ and CD8+ Cells in Peripheral Blood in Renal Transplant Patients With Cytomegalovirus Viremia

Transplantation Proceedings

Volumn 41, Issue 5, 2009, Pages 1639-1642

  Chen, J S ^a   Li, L S ^a   Cheng, D R ^a   Ji, S M ^a   Sun, Q Q ^a   Cheng, Z ^a   Wen, J Q ^a   Sha, G Z ^a   Liu, Z H ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE SUBPOPULATION; MALE; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; VIREMIA; VIRUS PNEUMONIA;

ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PNEUMONIA; PNEUMONIA, VIRAL; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 67249093780     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.01.085     Document Type: Article

References (19)

1. Villacian J.S., and Paya C.V. Prevention of infections in solid organ transplant recipients. Transpl Infect Dis 1 (1999) 50
2. Capulong M.G., Mendoza M., and Chavez J. Cytomegalovirus pneumonia in renal transplant patients. Transplant Proc 30 (1998) 3151
3. Engstrand M., Tournay C., Peyrat M.A., et al. Characterization of CMV pp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 69 (2000) 2243
4. Sester M., Sester U., Gartner B.C., et al. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 13 (2002) 2577
5. Sun Q., Li L., Ji S., et al. Variation of CD4+ and CD8+ T lymphocytes as predictor of outcome in renal allograft recipients who developed acute respiratory distress syndrome caused by cytomegalovirus pneumonia. Transplant Proc 37 (2005) 2118
6. Snydman D.R., Falagas M.E., Averv R., et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 33 (2001) 2571
7. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 32 (2001) 742
8. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. The International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340 (1999) 1462
9. Razonable R.R., Rivero A., Rodriguez A., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J infect Dis 184 (2001) 1461
10. Reinhardt R.L., Khoruts A., Merica R., et al. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410 (2001) 101
11. Jenkins M.K., Khoruts A., Ingulli E., et al. In vivo activation of antigen specific CD4 T cells. Annu Rev Immunol 19 (2001) 23
12. + T cells in protection against CMV disease. Blood 101 (2003) 2686
13. Radha R., Jordan S., Puliyada D., et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 5 (2005) 110
14. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 (2002) 3916
15. Kuypers D.R.J. Immunosuppressive drug monitoring-what to use in clinical practice today to improve renal graft outcome. Transpl Int 18 (2005) 140
16. Cattanco D., Perico N., Remuzzi G., et al. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant 4 (2004) 299
17. Del Tacca M. Prospects for personalized immunosuppression: pharmacologic tools. Transplant Proc 36 (2004) 687
18. Evans W.E., and Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 249 (2004) 464
19. Fredericks S., and Holt D.W. Pharmacogenomics of immunosuppressive drug metabolism. Curr Opin Nephrol Hypertens 12 (2003) 607